文献速递前列腺癌

观察管理的局限性前列腺癌患者的监测检查使用情况

Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
PubMed 文献 · J Urol · 2023-02-08

该回顾性队列研究纳入2004—2016年确诊低危或中危前列腺癌、初始观察至少12个月的10639例Medicare受益人,中位随访4.3年。观察5年者中98%至少接受1次PSA检测、48.0%至少接受1次额外前列腺活检、31.0%至少接受1次前列腺MRI;PSA检测与活检率随时间上升(RR 1.02和RR 1.10)。作者结论认为重复前列腺活检等推荐监测检查的使用率仍低。

要点

  • 观察5年的患者中98%至少接受1次PSA检测,48.0%至少接受1次额外前列腺活检。
  • 观察5年的患者中31.0%至少接受1次前列腺MRI。
  • PSA检测率随时间上升(RR 1.02,95% CI 1.02-1.03),活检率亦上升(RR 1.10,95% CI 1.08-1.11)。

核心结论

  • 在接受观察的低危和中危前列腺癌Medicare受益人中,包括重复前列腺活检在内的推荐监测检查使用率仍然较低。

研究设计与样本

  • 回顾性队列研究,纳入2004—2016年确诊低危或中危前列腺癌、初始观察至少12个月的Medicare受益人10639例,中位年龄73岁(IQR 69-77),中位随访4.3年(IQR 2.7-6.6)。

主要发现

  • 观察5年且未治疗的患者中,98%至少接受1次PSA检测,48.0%至少接受1次额外前列腺活检,31.0%至少接受1次前列腺MRI。
  • 观察至少12个月的患者中,混合效应泊松回归显示PSA检测率随时间上升(每日历年的RR 1.02,95% CI 1.02-1.03),活检率亦上升(每日历年的RR 1.10,95% CI 1.08-1.11)。
  • 年龄、临床风险、种族/民族、普查区贫困水平和地区等临床与社会人口学因素与活检率和PSA检测率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is unknown whether compliance with recommended monitoring tests during observation of localized prostate cancer has changed over time. MATERIALS AND METHODS: We performed a retrospective cohort study of Medicare beneficiaries diagnosed with low- or intermediate-risk prostate cancer in 2004-2016 who were initially managed with observation for a minimum of 12 months. The primary objective was to examine rates of PSA testing, prostate biopsy, and prostate MRI. We used multivariable mixed effects Poisson regression to determine whether rates of PSA testing and prostate biopsy increased over time. In addition, we identified clinical, sociodemographic, and provider factors associated with the frequency of monitoring tests during observation. RESULTS: We identified 10,639 patients diagnosed at a median age of 73 (IQR 69-77) years. The median follow-up time was 4.3 (IQR 2.7-6.6) years after diagnosis. Among patients managed without treatment for 5 years, 98% received at ≥1 PSA test, 48.0% ≥1 additional prostate biopsy, and 31.0% ≥1 prostate MRI. Among patients managed with observation for ≥12 months, mixed effects Poisson regression revealed that rates of PSA testing and biopsy increased over time (per calendar year: RR 1.02, 95% CI: 1.02-1.03 and RR 1.10, 95% CI: 1.08-1.11, respectively). Clinical and sociodemographic factors including age, clinical risk, race/ethnicity, census tract poverty, and region were associated with rates of biopsy and PSA testing. CONCLUSIONS: Use of recommended monitoring tests including repeat prostate biopsy remains low among Medicare beneficiaries undergoing observation for low- and intermediate-risk prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Leapman MS, Wang R, Loeb S, et al. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. J Urol. 2023. PMID: 36753746. doi:10.1097/JU.0000000000003159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。